CRP and congestive heart failure: No adverse events reportedSignificant beneficial effects in the NMES group: Peak VO2 (9.8%), Big-endothelin pmol/L (-25%), CRP mg/L (-65.3%)Significant beneficial effects in the aerobic ET group: Peak VO2 (11.2%), Big-endothelin pmol/L (-8.2%), CRP mg/L (-60%)Aforementioned improvements were not statistically significant between groupsNo changes in LDL, HDL and glucose levelPositive effect after 12 weeks of ET or NMES on arterial stiffness and autonomic balance in patients with moderate CHF